DBV Technologies S.A. - American Depositary Shares (DBVT)
9.0900
-0.5100 (-5.31%)
NASDAQ · Last Trade: May 21st, 3:36 PM EDT
Detailed Quote
Previous Close
9.600
Open
9.310
Bid
9.010
Ask
9.130
Day's Range
9.090 - 9.630
52 Week Range
0.4409 - 12.78
Volume
56,211
Market Cap
500.83M
PE Ratio (TTM)
-9.880
EPS (TTM)
-0.9
Dividend & Yield
N/A (N/A)
1 Month Average Volume
112,592
Chart
About DBV Technologies S.A. - American Depositary Shares (DBVT)
Dbv Technologies is a biopharmaceutical company focused on developing innovative therapies for patients with food allergies, particularly peanut allergies. Utilizing its proprietary Systemic Immunotherapy platform, the company aims to create treatments that help desensitize individuals to allergens, ultimately enhancing their quality of life and reducing the risk of severe allergic reactions. By leveraging advanced medical technology and a rigorous clinical development approach, Dbv Technologies strives to bring novel, breakthrough solutions to the field of immunotherapy for food allergies. Read More
Curious to know what's happening on the US markets one hour before the close of the markets on Tuesday? Join us as we explore the top gainers and losers in today's session.
DBV Technologies secured up to $306.9M to advance its Viaskin Peanut program. The funding supports FDA submission, commercialization and ongoing pediatric peanut allergy treatment research.
DBV Technologies secures FDA guidance for Accelerated Approval of its Viaskin Peanut patch, advancing treatment for toddlers with peanut allergies through pivotal trials.
